WuXi Biologics Achieves ANVISA GMP Certification for Cancer Therapy Production
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has recently achieved a significant milestone by obtaining Good Manufacturing Practice (GMP) certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). This achievement is a testament to WuXi Biologics' commitment to quality and compliance, assuring clients of its robust end-to-end commercial manufacturing services.
The certification pertains to two of its manufacturing facilities located in Wuxi: Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1), along with the Drug Product Packaging Center (DPPC). All three facilities successfully passed ANVISA's comprehensive five-day inspection with zero findings, underlining WuXi Biologics' rigorous quality management systems and effective coordination across its operations. This latest accolade not only affirms the company’s capability to support clients in global commercial manufacturing but also positions WuXi Biologics as a key player in the realm of cancer immunotherapy.
According to Dr. Chris Chen, CEO of WuXi Biologics, receiving the ANVISA GMP certification underscores the company’s unwavering dedication to adhering to global quality standards and regulatory compliance. He emphasized that this achievement enhances their ability to assist partners in launching innovative therapies in key markets, including Latin America. By accelerating the development and delivery of high-quality biologics at an affordable cost, WuXi Biologics is actively contributing to expanding patient access to advanced medical solutions.
WuXi Biologics has a proven track record of meeting stringent quality standards in the biotechnology field. As of the end of 2025, the organization had passed 46 regulatory inspections, including assessments from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company boasts a commendable 100% pass rate for FDA Pre-License Inspections and has completed over 1,800 GMP quality audits globally, reinforcing its reputation for excellence and reliability in manufacturing.
Within its expansive global network, WuXi Biologics operates 15 GMP-certified drug substance and drug product facilities, which provide seamless manufacturing processes for innovative biologic therapies. The integrated capabilities of MFG2, DP1, and DPPC encompass large-scale biologics drug manufacture, clinical and commercial drug product filling, as well as tailored packaging solutions. This unified approach not only enhances operational efficiencies but also ensures that all regulatory requirements are met across different global markets.
Moreover, WuXi Biologics continuously invests in advanced digital technologies that optimize the entire biopharmaceutical value chain, facilitating better client experiences and swifter project timelines. As of April 2026, the company is supporting a myriad of integrated client projects, reflecting its strategic focus on biopharmaceutical development, including those in late-stage clinical trials and commercial production. Currently, WuXi Biologics is involved in 982 client projects, with an increasing share devoted to complex modalities, indicative of its leadership in innovation within the sector.
Sustainability stands as a core principle for WuXi Biologics, which strives to deliver Green CRDMO solutions while adhering to exemplary Environmental, Social, and Governance (ESG) practices. By fostering collaboration with stakeholders, the company aims to mitigate its environmental footprint and promote responsible operations across its supply chain.
In summary, WuXi Biologics' receipt of the ANVISA GMP certification not only highlights its operational excellence but also reaffirms its strategic commitment to expanding its global footprint in cancer immunotherapy manufacturing. As the company continues its journey towards innovation and enhanced patient care, it remains dedicated to leveraging its resources to open new avenues in biopharmaceutical commercialization.
For more details about WuXi Biologics and their contributions to the biotechnology industry, please visit www.wuxibiologics.com.
The certification pertains to two of its manufacturing facilities located in Wuxi: Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1), along with the Drug Product Packaging Center (DPPC). All three facilities successfully passed ANVISA's comprehensive five-day inspection with zero findings, underlining WuXi Biologics' rigorous quality management systems and effective coordination across its operations. This latest accolade not only affirms the company’s capability to support clients in global commercial manufacturing but also positions WuXi Biologics as a key player in the realm of cancer immunotherapy.
According to Dr. Chris Chen, CEO of WuXi Biologics, receiving the ANVISA GMP certification underscores the company’s unwavering dedication to adhering to global quality standards and regulatory compliance. He emphasized that this achievement enhances their ability to assist partners in launching innovative therapies in key markets, including Latin America. By accelerating the development and delivery of high-quality biologics at an affordable cost, WuXi Biologics is actively contributing to expanding patient access to advanced medical solutions.
WuXi Biologics has a proven track record of meeting stringent quality standards in the biotechnology field. As of the end of 2025, the organization had passed 46 regulatory inspections, including assessments from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company boasts a commendable 100% pass rate for FDA Pre-License Inspections and has completed over 1,800 GMP quality audits globally, reinforcing its reputation for excellence and reliability in manufacturing.
Within its expansive global network, WuXi Biologics operates 15 GMP-certified drug substance and drug product facilities, which provide seamless manufacturing processes for innovative biologic therapies. The integrated capabilities of MFG2, DP1, and DPPC encompass large-scale biologics drug manufacture, clinical and commercial drug product filling, as well as tailored packaging solutions. This unified approach not only enhances operational efficiencies but also ensures that all regulatory requirements are met across different global markets.
Moreover, WuXi Biologics continuously invests in advanced digital technologies that optimize the entire biopharmaceutical value chain, facilitating better client experiences and swifter project timelines. As of April 2026, the company is supporting a myriad of integrated client projects, reflecting its strategic focus on biopharmaceutical development, including those in late-stage clinical trials and commercial production. Currently, WuXi Biologics is involved in 982 client projects, with an increasing share devoted to complex modalities, indicative of its leadership in innovation within the sector.
Sustainability stands as a core principle for WuXi Biologics, which strives to deliver Green CRDMO solutions while adhering to exemplary Environmental, Social, and Governance (ESG) practices. By fostering collaboration with stakeholders, the company aims to mitigate its environmental footprint and promote responsible operations across its supply chain.
In summary, WuXi Biologics' receipt of the ANVISA GMP certification not only highlights its operational excellence but also reaffirms its strategic commitment to expanding its global footprint in cancer immunotherapy manufacturing. As the company continues its journey towards innovation and enhanced patient care, it remains dedicated to leveraging its resources to open new avenues in biopharmaceutical commercialization.
For more details about WuXi Biologics and their contributions to the biotechnology industry, please visit www.wuxibiologics.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.